BPC-157 vs ARA-290

What Are BPC-157 and ARA-290?

BPC-157 (Body Protection Compound-157) is a Pentadecapeptide (15 amino acids). Derived from a protective protein found in human gastric juice. It is researched for tissue repair, gut healing, tendon and ligament recovery, wound healing, neuroprotection.

ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide. Synthetic 11-amino acid peptide engineered from the tissue-protective domain of erythropoietin (EPO). It is researched for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.

While both are popular research peptides, they work through fundamentally different mechanisms and serve different primary purposes.

How Do BPC-157 and ARA-290 Work Differently?

BPC-157 mechanism: BPC-157 upregulates growth hormone receptors and promotes angiogenesis (new blood vessel formation) through the FAK-paxillin pathway, which is critical for cell migration and tissue repair. It modulates the nitric oxide system and influences the dopaminergic, serotonergic, and GABAergic neurotransmitter systems. Research also shows it accelerates the formation of reticulin and collagen fibers during wound healing.

ARA-290 mechanism: Selectively activates the innate repair receptor (IRR), a CD131/EPOR heterodimer, triggering anti-inflammatory and tissue-protective signaling without any effect on red blood cell production. Suppresses microglia activation and pro-inflammatory cytokine release. Dose-dependently reduces neuropathic pain through central inflammation suppression.

These distinct mechanisms are why the two peptides are often used for different research goals — or combined to target multiple pathways.

How Do the Dosing Protocols Compare?

BPC-157: 200-500 mcg administered once or twice daily via subcutaneous or intramuscular injection, oral. Half-life: approximately 4 hours (stable form). Cycle: 4-12 weeks.

ARA-290: 2-4 mg daily administered once daily via subcutaneous injection. Half-life: approximately 24 hours. Cycle: 28 days typical; 8-16 weeks for extended response.

Use our peptide calculator for reconstitution math for either compound.

How Do the Benefits Compare?

BPC-157 benefits: tissue repair, gut healing, tendon and ligament recovery, wound healing, neuroprotection.

ARA-290 benefits: neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.

The overlap in benefits determines whether these peptides compete for the same use case or complement each other in a stack.

How Do the Side Effects Compare?

BPC-157: Generally well-tolerated in research. Minor injection site reactions reported. No significant adverse effects documented in animal studies at therapeutic doses. Long-term human safety data is not yet available.

ARA-290: Safe profile in multiple clinical trials. Minimal reported adverse events. Occasional mild injection site reactions. No serious safety concerns identified across diabetes, sarcoidosis, and neuropathy patient populations.

Can You Stack BPC-157 and ARA-290 Together?

Many researchers combine BPC-157 and ARA-290 in stacking protocols. The different mechanisms mean they can potentially provide complementary effects without competing for the same receptors.

Pairs synergistically with TB-500 in the 'Wolverine Stack' for comprehensive tissue repair — BPC-157 handles gut and tendon healing while TB-500 addresses systemic inflammation and cardiac repair. See our stacking guide for general principles.

Which Is Better: BPC-157 or ARA-290?

There is no universal answer. BPC-157 may be preferable for researchers focused on tissue repair, while ARA-290 is stronger for neuropathic pain relief.

For the most comprehensive results, many researchers combine both. Review each compound's individual guide for detailed protocols: BPC-157 | ARA-290.

Frequently Asked Questions